$KRBP
Kiromic Biopharma, Inc.

2023 Q2 Form 10-K Financial Statement

#000155837023006085 Filed on April 17, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.415M $3.591M $17.67M
YoY Change -48.42% -47.93% 26.76%
% of Gross Profit
Research & Development $1.967M $3.330M $13.92M
YoY Change -49.32% -0.23% 22.45%
% of Gross Profit
Depreciation & Amortization $549.6K $554.9K $1.673M
YoY Change 37.71% 300.36% 256.19%
% of Gross Profit
Operating Expenses $4.293M $6.921M $31.11M
YoY Change -49.1% -32.38% 20.9%
Operating Profit -$4.293M -$31.11M
YoY Change -49.1% 20.9%
Interest Expense -$335.4K -$159.6K $166.5K
YoY Change -12522.22% 2605.08% 1264.75%
% of Operating Profit
Other Income/Expense, Net -$366.5K $0.00 $0.00
YoY Change -100.0% -100.0%
Pretax Income -$6.764M -$7.068M -$34.73M
YoY Change -19.81% -33.54% 35.73%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.764M -$7.155M -$34.73M
YoY Change -19.81% -32.73% 35.73%
Net Earnings / Revenue
Basic Earnings Per Share -$3.22 -$64.42
Diluted Earnings Per Share -$3.22 -$11.78 -$64.42
COMMON SHARES
Basic Shares Outstanding 979.2K 18.25M 544.5K
Diluted Shares Outstanding 1.054M 544.5K

Balance Sheet

Concept 2023 Q2 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.704M $645.2K $645.2K
YoY Change -58.46% -97.46% -97.46%
Cash & Equivalents $2.704M $645.2K $645.2K
Short-Term Investments
Other Short-Term Assets $2.009M $1.044M $1.044M
YoY Change 31.95% -38.58% -38.58%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $4.713M $1.689M $1.689M
YoY Change -41.33% -93.76% -93.76%
LONG-TERM ASSETS
Property, Plant & Equipment $7.062M $8.137M $10.25M
YoY Change -22.89% 124.22% 182.56%
Goodwill $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $21.40K $24.40K $24.40K
YoY Change -31.19% -21.54% -21.54%
Total Long-Term Assets $8.924M $10.28M $10.28M
YoY Change -22.32% 180.83% 180.83%
TOTAL ASSETS
Total Short-Term Assets $4.713M $1.689M $1.689M
Total Long-Term Assets $8.924M $10.28M $10.28M
Total Assets $13.64M $11.97M $11.97M
YoY Change -30.14% -61.06% -61.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.622M $7.308M $7.308M
YoY Change 59.03% 230.04% 230.04%
Accrued Expenses $3.816M $1.608M $1.608M
YoY Change 125.74% 117.02% 117.02%
Deferred Revenue
YoY Change
Short-Term Debt $227.6K $557.2K $4.367M
YoY Change 98.09% 22.6% 860.86%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.70M $13.28M $13.28M
YoY Change 213.29% 289.56% 289.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $2.914M $2.914M
YoY Change
Other Long-Term Liabilities $1.232M $1.545M $1.545M
YoY Change -30.42%
Total Long-Term Liabilities $1.232M $4.459M $4.459M
YoY Change -30.42%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.70M $13.28M $13.28M
Total Long-Term Liabilities $1.232M $4.459M $4.459M
Total Liabilities $19.93M $17.74M $17.74M
YoY Change 157.54% 420.33% 420.33%
SHAREHOLDERS EQUITY
Retained Earnings -$114.0M -$101.9M
YoY Change 37.33% 51.67%
Common Stock $1.176K $648.00
YoY Change -87.35% -93.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.295M -$5.775M -$5.775M
YoY Change
Total Liabilities & Shareholders Equity $13.64M $11.97M $11.97M
YoY Change -30.14% -61.06% -61.06%

Cashflow Statement

Concept 2023 Q2 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$6.764M -$7.155M -$34.73M
YoY Change -19.81% -32.73% 35.73%
Depreciation, Depletion And Amortization $549.6K $554.9K $1.673M
YoY Change 37.71% 300.36% 256.19%
Cash From Operating Activities -$6.461M -$4.102M -$23.75M
YoY Change 8.24% -55.24% 16.85%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $57.20K $4.881M
YoY Change -100.0% -105.21% 157.57%
Acquisitions
YoY Change
Other Investing Activities $15.00K $15.00K
YoY Change -82.14%
Cash From Investing Activities $0.00 -$42.20K -$4.866M
YoY Change -100.0% -96.15% 168.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.111M 4.357M 3.903M
YoY Change -4263.29% 858.47% -89.55%
NET CHANGE
Cash From Operating Activities -6.461M -4.102M -23.75M
Cash From Investing Activities 0.000 -42.20K -4.866M
Cash From Financing Activities 7.111M 4.357M 3.903M
Net Change In Cash 649.9K 212.5K -24.71M
YoY Change -107.55% -102.17% -262.52%
FREE CASH FLOW
Cash From Operating Activities -$6.461M -$4.102M -$23.75M
Capital Expenditures $0.00 $57.20K $4.881M
Free Cash Flow -$6.461M -$4.160M -$28.63M
YoY Change 84.78% -48.44% 28.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001792581
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
648384
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
516284
CY2022Q2 krbp Operating Lease Termination Period After Notice Of Cancellation
OperatingLeaseTerminationPeriodAfterNoticeOfCancellation
P90D
CY2021Q3 krbp Operating Lease Termination Period After Notice Of Cancellation
OperatingLeaseTerminationPeriodAfterNoticeOfCancellation
P90D
CY2021Q4 krbp Operating Lease Termination Period After Notice Of Cancellation
OperatingLeaseTerminationPeriodAfterNoticeOfCancellation
P90D
CY2021Q3 us-gaap Warrants And Rights Outstanding Valuation Technique Extensible List
WarrantsAndRightsOutstandingValuationTechniqueExtensibleList
http://fasb.org/us-gaap/2021-01-31#ValuationTechniqueOptionPricingModelMember
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-39169
CY2022 dei Entity Registrant Name
EntityRegistrantName
Kiromic BioPharma, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4762913
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
7707 Fannin Street
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77054
CY2022 dei City Area Code
CityAreaCode
832
CY2022 dei Local Phone Number
LocalPhoneNumber
968-4888
CY2022 dei Security12b Title
Security12bTitle
Common Shares, par value $0.001 per share
CY2022 dei Trading Symbol
TradingSymbol
KRBP
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
6731623
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
979243
CY2022 dei Auditor Firm
AuditorFirmId
726
CY2022 dei Auditor Name
AuditorName
Whitley Penn
CY2022 dei Auditor Location
AuditorLocation
Houston, Texas
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
645200
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25353900
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16200
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1043700
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1699400
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1688900
CY2021Q4 us-gaap Assets Current
AssetsCurrent
27069500
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8136900
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3629000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2117300
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
24400
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
31100
CY2022Q4 us-gaap Assets
Assets
11967500
CY2021Q4 us-gaap Assets
Assets
30729600
CY2022Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
3809900
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7308100
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2214300
CY2022Q4 krbp Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
881600
CY2021Q4 krbp Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
741000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
142100
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
557200
CY2021Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
454500
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
584400
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13283300
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3409800
CY2022Q4 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
2914000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1544900
CY2022Q4 us-gaap Liabilities
Liabilities
17742200
CY2021Q4 us-gaap Liabilities
Liabilities
3409800
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
648384
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
516284
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
648
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
516
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
96172152
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
94535784
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101947500
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67216500
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5774700
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
27319800
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11967500
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30729600
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13920400
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11367800
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17193900
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13937900
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
430000
CY2022 us-gaap Operating Expenses
OperatingExpenses
31114300
CY2021 us-gaap Operating Expenses
OperatingExpenses
25735700
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-31114300
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-25735700
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
105800
CY2021 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
53400
CY2022 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-3463000
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
12800
CY2022 us-gaap Interest Expense
InterestExpense
166500
CY2021 us-gaap Interest Expense
InterestExpense
12200
CY2022 krbp Other Income Expense
OtherIncomeExpense
-3616700
CY2021 krbp Other Income Expense
OtherIncomeExpense
147000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-34731000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-25588700
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-64.42
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-64.42
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-67.82
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-67.82
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
544475
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
544475
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
380569
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
380569
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
11362100
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
36288900
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
829200
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
125400
CY2021 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
400000
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
140000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3762900
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-25588700
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24708700
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15203400
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25353900
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10150500
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
645200
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25353900
CY2022 us-gaap Interest Paid Net
InterestPaidNet
12200
CY2021 us-gaap Interest Paid Net
InterestPaidNet
12200
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1303000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
138000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
27319800
CY2022 krbp Adjustments To Additional Paid In Capital Amortization Of Common Stock Discount
AdjustmentsToAdditionalPaidInCapitalAmortizationOfCommonStockDiscount
344800
CY2022 krbp Adjustments To Additional Paid In Capital Warrant Fair Value
AdjustmentsToAdditionalPaidInCapitalWarrantFairValue
344800
CY2022 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
399400
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1237100
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-34731000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5774700
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-34731000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-25588700
CY2022 us-gaap Depreciation
Depreciation
1673400
CY2021 us-gaap Depreciation
Depreciation
469800
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9900
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1237100
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3762900
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
105800
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
12800
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
430000
CY2022 krbp Gain Loss Related To Litigation Settlement Net Of Cash Payments
GainLossRelatedToLitigationSettlementNetOfCashPayments
-3313400
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
394200
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-16200
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9800
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-655700
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1117400
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-6700
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3790800
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1411100
CY2022 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
142100
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
140600
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
406800
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-382200
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23745900
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20321500
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4880500
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1894800
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
15000
CY2021 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
84000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4865500
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1810800
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40000000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2881900
CY2022 us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
610700
CY2021 us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
665900
CY2022 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
508000
CY2021 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
573700
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4000000
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
200000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
125400
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3902700
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37335700
CY2022 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
399400
CY2021 us-gaap Stock Issued1
StockIssued1
400000
CY2021 krbp Restricted Stock Granted
RestrictedStockGranted
140000
CY2021 us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
456000
CY2022 krbp Right Of Use Asset Obtained In Exchange For Operating Lease Liability Asc842 Implementation
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityAsc842Implementation
2232700
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
303662
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23745900
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101947500
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Use of Estimates</b><span style="font-family:'Times New Roman','Times','serif';">—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, fair value of purchase price allocations of intangible assets associated with acquisitions, and estimating services incurred by third-party service providers used to recognize research and development expense.</span></p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Concentrations of Credit Risk and Other Uncertainties</b>—Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">The Company records receivables resulting from activities under its research grant from an academic institution. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the academic institution.</p>
CY2022Q4 krbp Number Of Lease Facility
NumberOfLeaseFacility
1
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
430000
CY2021Q4 us-gaap Goodwill
Goodwill
0
CY2022Q4 us-gaap Goodwill
Goodwill
0
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1031500
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8136900
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3629000
CY2022 us-gaap Depreciation
Depreciation
1673400
CY2021 us-gaap Depreciation
Depreciation
469800
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
291832
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4660500
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2700300
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-34731000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-25588700
CY2022 krbp Adjustments To Additional Paid In Capital Warrant Discount Amortization
AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization
100000
CY2021 krbp Adjustments To Additional Paid In Capital Warrant Discount Amortization
AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization
100000
CY2022 krbp Common Stock Amortization Of Discount
CommonStockAmortizationOfDiscount
244800
CY2021 krbp Common Stock Amortization Of Discount
CommonStockAmortizationOfDiscount
122000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35075800
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-35075800
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25810700
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-25810700
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
544475
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
544475
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
380569
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
380569
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-64.42
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-64.42
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-67.82
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-67.82
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10837200
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2399100
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
212900
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
467100
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
668700
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
273900
CY2022Q4 krbp Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
881600
CY2021Q4 krbp Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
741000
CY2021Q4 krbp Number Of Independent Directors Special Committee
NumberOfIndependentDirectorsSpecialCommittee
3
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
269800
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2129300
CY2022 krbp Short Term Lease Monthly Rental Payments
ShortTermLeaseMonthlyRentalPayments
2500
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
22500
CY2022 us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
CY2021Q3 krbp Operating Lease Additional Square Footage
OperatingLeaseAdditionalSquareFootage
15385
CY2021Q4 krbp Number Of Lease Amendments
NumberOfLeaseAmendments
2
CY2021Q4 krbp Operating Lease Additional Square Footage
OperatingLeaseAdditionalSquareFootage
3684
CY2022Q2 krbp Operating Lease Additional Square Footage
OperatingLeaseAdditionalSquareFootage
9352
CY2022Q2 krbp Lessee Operating Lease Payments Per Month Years One And Two
LesseeOperatingLeasePaymentsPerMonthYearsOneAndTwo
4800
CY2022Q2 krbp Lessee Operating Lease Payments Per Month Years Three And Four
LesseeOperatingLeasePaymentsPerMonthYearsThreeAndFour
4896
CY2022Q2 krbp Lessee Operating Lease Payments Per Month Year Five
LesseeOperatingLeasePaymentsPerMonthYearFive
5000
CY2022Q2 krbp Operating Lease Lease Cancellation Termination Payment Number Of Months Rent
OperatingLeaseLeaseCancellationTerminationPaymentNumberOfMonthsRent
3
CY2022Q3 krbp Operating Lease Additional Square Footage
OperatingLeaseAdditionalSquareFootage
1458
CY2022Q3 krbp Lessee Operating Lease Payments Per Month Year One
LesseeOperatingLeasePaymentsPerMonthYearOne
2430
CY2022Q3 krbp Lessee Operating Lease Payments Per Month Years Two And Three
LesseeOperatingLeasePaymentsPerMonthYearsTwoAndThree
2490
CY2022Q3 krbp Lessee Operating Lease Payments Per Month Year Five
LesseeOperatingLeasePaymentsPerMonthYearFive
2552
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2117300
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2117300
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
584400
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1544900
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2129300
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
663100
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M2D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0712
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
714000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
717600
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
724700
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
242800
CY2021 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
420500
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 krbp Common Stock Value Aggregate Proceeds From Issuances Net Of Offering Costs And Discount Amortization
CommonStockValueAggregateProceedsFromIssuancesNetOfOfferingCostsAndDiscountAmortization
48264300
CY2020Q4 krbp Common Stock Value Aggregate Proceeds From Issuances Net Of Offering Costs And Discount Amortization
CommonStockValueAggregateProceedsFromIssuancesNetOfOfferingCostsAndDiscountAmortization
11975400
CY2022Q4 krbp Common Stock Value Aggregate Proceeds From Issuances Net Of Offering Costs And Discount Amortization
CommonStockValueAggregateProceedsFromIssuancesNetOfOfferingCostsAndDiscountAmortization
48609100
CY2021Q4 krbp Common Stock Value Aggregate Proceeds From Issuances Net Of Offering Costs And Discount Amortization
CommonStockValueAggregateProceedsFromIssuancesNetOfOfferingCostsAndDiscountAmortization
48264300
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.21
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12668900
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8135900
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3371900
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4169200
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
874400
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
874400
CY2022Q4 krbp Deferred Tax Assets Irc Section174 Research And Experimental Expenditures
DeferredTaxAssetsIrcSection174ResearchAndExperimentalExpenditures
2293000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
105800
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
88500
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
95300
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
428400
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
158500
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
19989400
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
13274800
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19563500
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
13274100
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
700
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
425900

Files In Submission

Name View Source Status
krbp-20221231_cal.xml Edgar Link unprocessable
krbp-20221231_pre.xml Edgar Link unprocessable
0001558370-23-006085-index-headers.html Edgar Link pending
0001558370-23-006085-index.html Edgar Link pending
0001558370-23-006085.txt Edgar Link pending
0001558370-23-006085-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
krbp-20221231.xsd Edgar Link pending
krbp-20221231x10k.htm Edgar Link pending
krbp-20221231x10k001.jpg Edgar Link pending
krbp-20221231x10k002.jpg Edgar Link pending
krbp-20221231x10k003.jpg Edgar Link pending
krbp-20221231x10k004.jpg Edgar Link pending
krbp-20221231x10k005.jpg Edgar Link pending
krbp-20221231x10k006.jpg Edgar Link pending
krbp-20221231x10k007.jpg Edgar Link pending
krbp-20221231x10k008.jpg Edgar Link pending
krbp-20221231x10k009.jpg Edgar Link pending
krbp-20221231x10k010.jpg Edgar Link pending
krbp-20221231x10k011.jpg Edgar Link pending
krbp-20221231x10k012.jpg Edgar Link pending
krbp-20221231x10k013.jpg Edgar Link pending
krbp-20221231x10k014.jpg Edgar Link pending
krbp-20221231x10k015.jpg Edgar Link pending
krbp-20221231xex21d1.htm Edgar Link pending
krbp-20221231xex23d1.htm Edgar Link pending
krbp-20221231xex23d2.htm Edgar Link pending
krbp-20221231xex31d1.htm Edgar Link pending
krbp-20221231xex31d2.htm Edgar Link pending
krbp-20221231xex32d1.htm Edgar Link pending
krbp-20221231xex32d2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
krbp-20221231_lab.xml Edgar Link unprocessable
krbp-20221231_def.xml Edgar Link unprocessable
krbp-20221231x10k_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending